Laura Martin, MD is an Assistant Professor of Pediatrics at The Ohio State University College of Medicine. Her clinical interests include general pediatric hematology/oncology, cancer survivorship and palliative care. Her research interests include the role of glycans in solid tumor and lymphocyte biology.
Approximately 74 percent of Nationwide Children's eligible oncology patients are enrolled in a clinical trial, making Nationwide Children's Center for Hematology/Oncology/BMT among the leading cancer centers for clinical trial enrollment by the Children’s Oncology Group.
Nationwide Children's has almost 200 clinical trials underway to determine the safety and effectiveness of drug treatments in children, and is continuing to partner with leading researchers and companies around the world to help improve the outcomes of children with cancer.
For the children of central Ohio, this means that they never have to leave the comforts of Central Ohio to receive access to leading national and international trials and treatment protocols.
Learn more about clinical trials at Nationwide Children's.
Children’s Center for Childhood Cancer
Children’s Oncology Group (COG)
National Marrow Donor Program (NMDP)
National Cancer Institute (NCI)
National Institutes of Health (NIH)
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital/Richard J. Solove Research Institute
A clinical trial is a research study that tests the current, most promising treatments for diseases. Most clinical trials involve the testing of well-known medications given in new ways or in new combinations with other well-tested medications that are effective in that disease. The goal of a clinical trial is to identify treatment combinations that will provide the highest success rates or the best chance of a cure with the least amount of side effects. Carefully conducted clinical trials are the fastest and safest way to find treatments that work in people and ways to improve health.
Participants in clinical trials can play a more active role in their own health care, gain access to new research treatments before they are widely available, and help others by contributing to medical research.
All clinical trials have guidelines about who can participate. These criteria are based on such factors as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. Before joining a clinical trial, a participant must qualify for the study. It is important to note that these criteria are not used to reject people personally. Instead, the criteria are used to identify appropriate participants and keep them safe.
Three different phases of medical studies called clinical trials used to evaluate new treatments for childhood cancers, as well as other diseases. Each phase has a different goal.
Phase I studies are the most basic of clinical trials. Here, drugs are tested to evaluate the dosages of the treatment, and how often the treatment can be administered (maximum tolerated dosages, MTD). As it is unknown whether the treatment will be effective against a particular disease, people with a variety of diseases are enrolled. Drugs are given at gradually increasing dosages until there are unacceptable side effects (dose-limited toxicities, DLT).
Phase II studies use the results from Phase I studies regarding MTD and DLT. The treatment is targeted at the population of patients which responded most favorably in Phase I trials, because it is believed to hold promise for that particular group of patients.
Phase III studies are those that most children will receive when newly diagnosed. These studies will test the standard treatment (current best) against promising alternatives that may increase cure rates or decrease side effects or late effects of treatment.